Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 19, Issue 1, 2013, Pages 132-140

  Li, Yi ^a,b   Nuij, Veerle J A A ^a   Baars, Judith E ^a   Biermann, Katharina ^a   Kuipers, Ernst J ^a   Peppelenbosch, Maikel P ^a   De Haar, Colin ^a   Van Der Woude, C Janneke ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Prediction; SOCS3; STAT1; Ulcerative colitis

Indexed keywords

STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADULT; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; ENDOSCOPY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INTESTINE EPITHELIUM CELL; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REMISSION; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLONOSCOPY; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MUCOSITIS; PHOSPHORYLATION; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; YOUNG ADULT;

EID: 84873745079     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22992     Document Type: Article

References (26)

1. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
2. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518-1523.
3. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006;12:551-557.
4. Lauritsen K, Laursen LS, Bukhave K, et al. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut. 1988;29:1316-1321.
5. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
6. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009; 104: 673-678.
7. Garcia-Sanchez V, Gonzalez R, Iglesias-Flores E, et al. Can systemic cytokines predict relapse of inflammatory bowel disease? Hepatogastroenterology. 2010;57:524-530.
8. Louis E, Belaiche J, van Kemseke C, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol. 1997;9:939-944.
9. Higgins PD, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005;100:355-361.
10. Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol. 2004;25:434-440.
11. Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent generegulation by cytokines. Drug News Perspect. 2005;18:243-249.
12. Dimitriou ID, Clemenza L, Scotter AJ, et al. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol Rev. 2008;224:265-283.
13. Greenhalgh CJ, Miller ME, Hilton DJ, et al. Suppressors of cytokine signaling: relevance to gastrointestinal function and disease. Gastroenterology. 2002;123:2064-2081.
14. Grivennikov S, Karin E, Terzic J, et al. IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103-113.
15. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15:91-102.
16. Li Y, de Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010;59:227-235.
17. Bluyssen HA, Rastmanesh MM, Tilburgs C, et al. IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol. 2011;299:C354-362.
18. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups(update from 2002). Gut. 2010;59:666-689.
19. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000; 47:404-409.
20. Li Y, de Haar C, Peppelenbosch MP, et al. New insights into the role of STAT3 in IBD. Inflamm Bowel Dis. 2012;18:1177-1183.
21. Miyanaka Y, Ueno Y, Tanaka S, et al. Clinical significance of mucosal suppressors of cytokine signaling 3 expression in ulcerative colitis. World J Gastroenterol. 2007; 13:2939-2944.
22. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174-178.
23. Roda G, Caponi A, Benevento M, et al. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1239-1246.
24. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20.
25. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
26. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.